Overall treatment outcome - analysis of long-term results of rectal cancer treatment on the basis of a new parameter.
combined therapy
rectal cancer
treatment outcomes
Journal
Archives of medical science : AMS
ISSN: 1734-1922
Titre abrégé: Arch Med Sci
Pays: Poland
ID NLM: 101258257
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
05
2017
accepted:
12
11
2017
entrez:
17
6
2020
pubmed:
17
6
2020
medline:
17
6
2020
Statut:
epublish
Résumé
Outcomes of rectal cancer treatment depend on preoperative staging and the effectiveness of treatments. According to disease staging, different variants of combined therapy (surgery, chemo- and radiotherapy) are used. Available parameters such as overall survival rates and disease- free survival rates as well as the presence of recurrence are inaccurate and should be jointly considered. Data from 138 patients with rectal cancer (I-III WHO), who were radically operated on in the period 2001-2004 in Bydgoszcz Oncology Centre were analysed. Among this group 84 patients were radically operated on one week after preoperative radiotherapy 5 × 5 Gy (sRT). We established a new parameter, the overall treatment outcome (OTO), based on the finding that there was no recurrence (local recurrence, distant metastases) of the disease within 5 years, which is generally considered a good result for the treatment of rectal cancer. Among all patients ( In using a combined therapy, it is possible to optimise rectal cancer treatment outcomes. The OTO parameter is a useful tool for defining these results of cancer combination treatment.
Identifiants
pubmed: 32542084
doi: 10.5114/aoms.2020.94330
pii: 40331
pmc: PMC7286345
doi:
Types de publication
Journal Article
Langues
eng
Pagination
825-833Informations de copyright
Copyright © 2020 Termedia & Banach.
Références
Dis Colon Rectum. 2001 Apr;44(4):473-83; discussion 483-6
pubmed: 11330574
Dis Colon Rectum. 2007 Feb;50(2):156-67
pubmed: 17180256
Acta Oncol. 2016 Jun;55 Suppl 2:10-23
pubmed: 26859340
Lancet. 2001 Oct 20;358(9290):1291-304
pubmed: 11684209
Arch Med Sci. 2016 Feb 1;12(1):68-77
pubmed: 26925120
Lancet. 2009 Mar 7;373(9666):811-20
pubmed: 19269519
Gut. 2011 Aug;60(8):1087-93
pubmed: 21303917
Br J Surg. 2006 Oct;93(10):1215-23
pubmed: 16983741
Eur J Surg Oncol. 2010 Sep;36 Suppl 1:S74-82
pubmed: 20598844
Clin Exp Metastasis. 2016 Dec;33(8):765-773
pubmed: 27485175
Colorectal Dis. 2012 Jan;14(1):71-8
pubmed: 21199273
Surg Today. 2010 Jun;40(6):501-6
pubmed: 20496130
Ann Oncol. 2017 Jul 1;28(suppl_4):iv22-iv40
pubmed: 28881920
Ann Surg. 2007 Nov;246(5):693-701
pubmed: 17968156
J Am Coll Surg. 2006 May;202(5):732-6
pubmed: 16648012
Lancet. 1986 Jun 28;1(8496):1479-82
pubmed: 2425199
Dis Colon Rectum. 1990 May;33(5):432-8
pubmed: 2183979
Br J Surg. 1993 Oct;80(10):1333-6
pubmed: 8242317
Ann Surg. 1983 Aug;198(2):159-63
pubmed: 6870373
Dis Colon Rectum. 2011 Jun;54(6):672-80
pubmed: 21552050
Ann Oncol. 2005 Apr;16(4):664-72
pubmed: 15734777
World J Gastroenterol. 2010 Nov 14;16(42):5375-9
pubmed: 21072903
JAMA. 2000 Aug 23-30;284(8):1008-15
pubmed: 10944647
J Surg Oncol. 2006 Mar 1;93(3):173-80
pubmed: 16482596
Am J Surg. 2003 Jan;185(1):54-7
pubmed: 12531446
World J Surg. 2012 Jul;36(7):1686-92
pubmed: 22411086
World J Surg. 1992 Sep-Oct;16(5):848-57
pubmed: 1462619
J Clin Oncol. 2004 Oct 1;22(19):3958-64
pubmed: 15459218
Eur J Cancer. 2008 Aug;44(12):1710-6
pubmed: 18573654
Br J Surg. 2011 May;98(5):716-23
pubmed: 21341253
J R Coll Surg Edinb. 1998 Dec;43(6):393-6
pubmed: 9990786
Hepatogastroenterology. 2010 Sep-Oct;57(102-103):1099-105
pubmed: 21410039
N Engl J Med. 1997 Apr 3;336(14):980-7
pubmed: 9091798
J Am Coll Surg. 1995 Jun;180(6):705-12
pubmed: 7773484
Dis Colon Rectum. 2007 Nov;50(11):1783-99
pubmed: 17874269
J Clin Oncol. 1998 Jan;16(1):324-9
pubmed: 9440760
Lancet Oncol. 2011 Jun;12(6):575-82
pubmed: 21596621
N Engl J Med. 2001 Aug 30;345(9):638-46
pubmed: 11547717
Eur J Cancer. 2006 Sep;42(14):2212-21
pubmed: 16904315
Int J Colorectal Dis. 2009 Aug;24(8):923-9
pubmed: 19488771